The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson’s Disease by Inhibiting the NF-κB/NLRP3 Pathway

Exportin 1 (XPO1) is an important transport receptor that mediates the nuclear export of various proteins and RNA. KPT-8602 is a second-generation inhibitor of XPO1, demonstrating the lowest level of side effects, and is currently in clinical trials for the treatment of cancers. Previous studies sug...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuhan, Wang, Shengxiang, Gu, Runze, Che, Na, Wang, Jing, Cheng, Jinbo, Yuan, Zengqiang, Cheng, Yong, Liao, Yajin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200340/
https://www.ncbi.nlm.nih.gov/pubmed/35721113
http://dx.doi.org/10.3389/fphar.2022.847605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200340/
https://www.ncbi.nlm.nih.gov/pubmed/35721113
http://dx.doi.org/10.3389/fphar.2022.847605

Ejemplares similares